Strengthening tuberculosis control overseas: Who benefits?

Value in Health

Volumn 18, Issue 2, 2015, Pages 180-188

  Nguyen, Hoa Thi Minh ^a   Hickson, Roslyn I ^b,c   Kompas, Tom ^a   Mercer, Geoffry N ^d   Lokuge, Kamalini M ^d  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c IBM RESEARCH   (United States)

^d The Australian National University   (Australia)

Author keywords

Australia; cost benefit analysis; cost utility analysis; DOTS; metapopulation model; PNG; tuberculosis control

Indexed keywords

ARTICLE; AUSTRALIAN; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE TRANSMISSION; ECONOMIC EVALUATION; HEALTH CARE; HEALTH DISPARITY; HUMAN; INCIDENCE; PAPUA NEW GUINEAN; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SHORT COURSE THERAPY; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; AUSTRALIA; ECONOMICS; PAPUA NEW GUINEA; PROCEDURES;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; AUSTRALIA; COST-BENEFIT ANALYSIS; HUMANS; PAPUA NEW GUINEA; TUBERCULOSIS;

EID: 84924985995     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.11.008     Document Type: Article

References (63)

1. World Health Organization Global Tuberculosis Report 2012 2012 World Health Organization France
2. L. Gaudette, and E. Ellis Tuberculosis in Canada: a focal disease requiring distinct control strategies for different risk groups Tuber Lung Dis 74 1993 244 253
3. M.T. McKenna, E. McCray, and I. Onorato The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993 N Engl J Med 332 1995 1071 1076
4. F.G. Cobelens, H. van Deutekom, and I.W. Draayer-Jansen Association of tuberculin sensitivity in Dutch adults with history of travel to areas of with a high incidence of tuberculosis Clin Infect Dis 33 2001 300 304
5. R. Frothingham, J.E. Stout, and C.D. Hamilton Current issues in global tuberculosis control Int J Infect Dis 9 2005 297 311
6. N.J. Binkin, P.L. Zuber, and C.D. Wells Overseas screening for tuberculosis in immigrants and refugees to the United States: current status Clin Infect Dis 23 1996 1226 1232
7. N. Horsfield, and L. Ormerod Suspected cases of pulmonary tuberculosis referred from port of entry BMJ 292 1986 765
8. L. Bonvin, and J. Zellweger Mass miniature X-ray screening for tuberculosis among immigrants entering Switzerland Tuber Lung Dis 73 1992 322 325
9. R.E. Thomas, and B. Gushulak Screening and treatment of immigrants and refugees to Canada for tuberculosis: implications of the experience of Canada and other industrialized countries Can J Infect Dis 6 1995 246 255
10. G.G. Alvarez, B. Gushulak, and K.A. Rumman A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates BMC Infect Dis 11 2011 3
11. K. Schwartzman, O. Oxlade, and R.G. Barr Domestic returns from investment in the control of tuberculosis in other countries N Engl J Med 353 2005 1008 1020
12. World Health Organization The Stop TB Strategy: Building On and Enhancing DOTS to Meet the TB-Related Millennium Development Goals 2006 World Health Organization Geneva, Switzerland
13. World Health Organization Treatment of Tuberculosis Guidelines 4th ed 2006 World Health Organization Geneva
14. Lokuge K, Salee K, Konstantinos A. Tuberculosis control in the Torres Strait region: what's needed and why? Report following a public forum. Development Policy Centre Discussion Paper No. 22. Available from: http://papers.ssrn.com/ sol3/papers.cfm?abstract-id=2126915. [Accessed November 27, 2013].
15. A. Bassili, A. Seita, and S. Baghdadi Diagnostic and treatment delay in tuberculosis in 7 countries of the Eastern Mediterranean region Infect Dis Clin Pract 16 2008 23 35
16. McBryde E. Evaluation of risks of tuberculosis in Western Province Papua New Guinea. Available from: http://www.ausaid.gov.au/countries/pacific/png/Documents/png-tb-evaluation-of-risk.pdf. [Accessed November 21, 2013].
17. R.I. Hickson, G.N. Mercer, and K. Lokuge A metapopulation model of tuberculosis transmission with a case study from high to low burden areas PLoS One 7 2012 e34411
18. I. Hanski, and M.E. Gilpin Metapopulation Biology: Ecology, Genetics, and Evolution 1997 Elsevier Academic Press San Diego
19. I. Hanski, and O.E. Gaggiotti Ecology, Genetics, and Evolution of Metapopulations 2004 Elsevier Academic Press San Diego
20. M.J. Keeling, and P. Rohani Modeling Infectious Diseases in Humans and Animals 2008 Princeton University Press Princeton, NJ
21. Department of Immigration and Citizenship. Inquiry into matters relating to the Torres Strait region, submissions received by the committee. Available from: http://www.aph.gov.au/senate/committee/fadt-ctte/torresstrait/submissions.htm. [Accessed September 5, 2010].
22. M.C. Weinstein, J.E. Siegel, and M.R. Gold Recommendations of the Panel on Cost-Effectiveness in Health and Medicine JAMA 276 1996 1253 1258
23. T.T.T. Edejer, R. Baltussen, and T. Adam Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis 2003 World Health Organization Geneva, Switzerland
24. World Health Organization. Planning and Budgeting for TB Control. Papua New Guinea, Western Pacific Region. Version 4 (November 2010). Geneva, Switzerland: World Health Organization, 2010.
25. R. Baltussen, K. Floyd, and C. Dye Cost effectiveness analysis of strategies for tuberculosis control in developing countries BMJ 331 2005 1364
26. World Health Organization Diagnostics for Tuberculosis: Global Demand and Market Potential 2006 World Health Organization Geneva, Switzerland
27. Global Drug Facility. First-line drug calculation sheet. Available from: http://www.stoptb.org/gdf/monitoring/documents.asp. [Accessed May 8, 2012].
28. World Health Organization. Results of unit costs for patient services for the 14 global burden of disease regions. Available from: http://www.who.int/choice/costs/unit-regions/en/. [Accessed May 23, 2014].
29. M.F. Drummond, M.J. Sculpher, and G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes 2005 Oxford University Press New York, NY
30. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
31. C.J. Murray, and A.D. Lopez Global Comparative Assessments in the Health Sector: Disease Burden, Expenditures and Intervention Packages 1994 World Health Organization Geneva
32. Australian Bureau of Statistics. Population projections, Australia, 2006 to 2101. Available from: http://www.abs.gov.au. [Assessed June 10, 2013].
33. United Nations. World Population Prospects: The 2010 Revision. New York, NY: Population Division, Department of Economic and Social Affairs, United Nations. 2011. Available from: http://esa.un.org/unpd/wpp/index.htm. [Assessed May 27, 2013].
34. World Health Organization Global Tuberculosis Control: Report 2010 2010 World Health Organization Geneva, Switzerland
35. World Health Organization Global Tuberculosis Control: Report 2007 2007 World Health Organization Geneva, Switzerland
36. World Health Organization Global Tuberculosis Control: Report 2004 2004 World Health Organization Geneva, Switzerland
37. Australian Bureau of Statistics. Life tables, Australia, 2008-2010. Available from: http://www.abs.gov.au. [Assessed June 10, 2013].
38. World Health Organization. World health statistics. Life tables, Papua New Guinea, 2011. Available from: http://apps.who.int/gho/data/node.main.687?lang=en. [Assessed June 10, 2013].
39. E.J. Mishan Evaluation of life and limb: a theoretical approach J Pol Econ 4 1971 687 705
40. A. Marin, and G. Psacharopoulos The reward for risk in the labor market: evidence from the United Kingdom and a reconciliation with other studies J Pol Econ 90 1982 827 853
41. J.L. Pinto-Prades, G. Loomes, and R. Brey Trying to estimate a monetary value for the QALY J Health Econ 28 2009 553 562
42. J.A. Olsen, C. Donaldson, and J. Pereira The insensitivity of 'willingness-to-pay' to the size of the good: new evidence for health care J Econ Psychol 25 2004 445 460
43. R.D. Smith Sensitivity to scale in contingent valuation: the importance of the budget constraint J Health Econ 24 2005 515 529
44. A. Gafni, and S. Birch Incremental cost-effectiveness ratios (ICERs): the silence of the lambda Soc Sci Med 62 2006 2091 2100
45. A. Bobinac, N. van Exel, F.F. Rutten, and W.B. Brouwer Get more, pay more? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation J Health Econ 31 2012 158 168
46. T. Shiroiwa, Y.K. Sung, and T. Fukuda International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19 2010 422 437
47. A. Williams, and R. Sugden The Principles of Practical Cost-Benefit Analysis 1978 Oxford University Press New York
48. H.G. Eichler, S.X. Kong, and W.C. Gerth Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7 2004 518 528
49. D.A. Henry, S.R. Hill, and A. Harris Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme JAMA 294 2005 2630 2632
50. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 2004 437 452
51. M.D. Rawlins, and A.J. Culyer National Institute for Clinical Excellence and its value judgments BMJ 329 2004 224
52. B. George, A. Harris, and A. Mitchell Cost-effectiveness analysis and the consistency of decision making Pharmacoeconomics 19 2001 1103 1109
53. A. Bobinac, N. Van Exel, F.F. Rutten, and W.B. Brouwer Willingness to pay for a quality-adjusted life-year: the individual perspective Value Health 13 2010 1046 1055
54. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 2009;338:268-9.
55. J. Sachs Macroeconomics and Health: Investing in Health for Economic Development Report of the Commission on Macroeconomics and Health 2001 World Health Organization Geneva, Switzerland
56. D.B. Evans, T.T.T. Edejer, T. Adam, and S.S. Lim Achieving the millennium development goals for health: methods to assess the costs and health effects BMJ 331 2005 1137 1140
57. World Health Organization. Cost effectiveness thresholds. Available from: http://www.who.int/choice/costs/CER-thresholds/en/. [Accessed August 28, 2014].
58. A.R. Measham, G. Alleyne, and A. Mills Disease Control Priorities in Developing Countries 2006 World Bank and Oxford University Press Washington, DC
59. S. Blower, and H. Dowlatabadi Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example Int Stat Rev 62 1994 229 243
60. M.A. Sanchez, and S.M. Blower Uncertainty and sensitivity analysis of the basic reproductive rate: tuberculosis as an example Am J Epidemiol 145 1997 1127 1137
61. S. Marino, I.B. Hogue, C.J. Ray, and D.E. Kirschner A methodology for performing global uncertainty and sensitivity analysis in systems biology J Theor Biol 254 2008 178 196
62. E.G. Thomas, H.E. Barrington, K.M. Lokuge, and G.N. Mercer Modelling the spread of tuberculosis, including drug resistance and HIV: a case study in Papua New Guinea's Western Province ANZIAM J 52 2010 26 45
63. C. Murray, E. DeJonghe, and H. Chum Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries Lancet 338 1991 1305 1308